Bill > HR9070

This bill amends Title 35 of the United States Code to prohibit "product hopping" - a practice where brand-name drug manufacturers make minor changes to their products to extend their patent exclusivity and delay generic competition. The key provisions of the bill are: 1) It limits the number of patents a brand-name drug company can assert against a generic competitor to 20 patents, with a maximum of 10 issued after a certain date, with exceptions for good cause. 2) It requires the generic company to provide certain information to the brand-name company to enable them to form a reasonable belief about potential infringement. 3) It increases funding for the Medicare Improvement Fund by $1.8 billion. The overall intent of the bill is to facilitate earlier generic drug competition and improve patient access to more affordable prescription medications.

Health and Social Services, Justice

https://www.congress.gov/bill/118th-congress/house-bill/9070/all-info